Global Desmoid Tumors Market

Global Desmoid Tumors Market Size Insights Forecasts to 2035

• The Global Desmoid Tumors Market Size Was Estimated at USD 2.65 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.47 % from 2025 to 2035
• The Worldwide Desmoid Tumors Market Size is Expected to Reach USD 4.76 Billion by 2035
• North America is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Desmoid Tumors Market Size Was Worth Around USD 2.65 Billion In 2024 And Is Predicted To Grow To Around USD 4.76 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 5.47 % From 2025 To 2035. Better medical research, more money flowing into healthcare, and sharper tools for diagnosis. More individuals are being diagnosed with desmoid tumors these rare, stubborn soft tissue growths, which means there’s a bigger push for new and better treatments. The high demand is opening up the market and getting researchers to dig even deeper for fresh solutions.

 

Market Overview

The desmoid tumors market includes the global healthcare and pharmaceutical industry segment focused on the diagnosis, treatment, and management of desmoid tumors (also known as aggressive fibromatosis). Desmoid tumors, also called fibromatosis, are rare, noncancerous growths that develop in connective tissues like tendons, muscles, and ligaments. Although they aren’t cancerous, they can still cause serious problems because they tend to grow into and invade nearby tissues. Common signs include a noticeable lump or swelling and reduced movement in the affected area. Desmoid tumors can also be painful. In some cases, they press on nearby structures, causing issues such as bowel obstruction or nerve compression. They can be hard to diagnose because their symptoms and appearance often resemble other benign and malignant conditions. Desmoid tumors can look like other benign and malign paths of disease; diagnosing them can be difficult. Diagnostic testing generally consists of a complete physical examination, consideration of the patient's medical history, and some kind of imaging test (MRI, CT scan, etc.) to determine the exact location and extent of the desmoid tumor. Finally, to accurately diagnose a desmoid tumor and differentiate it from other more aggressive malignancies, a biopsy must be performed to confirm that it is a desmoid tumor.

 

Parabilis just made a major move in the biotech space: it raised $305 million in a Series F financing round to accelerate development of its tumor drug, with the stated goal of “upending the status quo.”

 

Report Coverage

This research report categorizes the desmoid tumors market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the desmoid tumors market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the desmoid tumors market.     

 

Driving Factors  

This change is driven by improvements in treatment methods and a better understanding of the disease. Desmoid tumors are known for being aggressive and having a high chance of returning. This has led to more research aimed at finding effective therapies. Healthcare providers and researchers explore the molecular details of these tumors, and new treatment options are emerging that could lead to better outcomes for patients. In addition, greater awareness of desmoid tumors among healthcare professionals and patients is likely to aid in early diagnosis and treatment, which can be crucial for managing this condition. Moreover, the global desmoid tumors market is shifting toward personalised medicine, where treatments are customised for individual patients. This trend reflects a larger movement in oncology, highlighting the need for targeted strategies that take genetic and environmental factors into account. Pharmaceutical companies invest in research and development, and the range of treatment options is expected to grow, giving hope to patients who have faced limited choices in the past. Overall, the market is likely to expand, supported by ongoing innovations and a commitment to improving care for those affected by desmoid tumors.

 

Restraining Factors  

The desmoid tumor treatment market has some things going for it. It also faces some big problems. One of the things holding it back is that the treatment is really expensive. This is especially true for kinds of treatment that target the tumor directly and for advanced surgery. These costs are so high that they can be too much for patients and healthcare systems to handle. The fact that desmoid tumors are rare and complicated also makes things tough. It is hard to diagnose them and figure out the way to treat them. This is because doctors and healthcare systems may not have the skills and resources they need to deal with these kinds of cases. The desmoid tumor treatment market is affected by these challenges.

 

Market Segmentation    

The desmoid tumors market share is classified into diagnosis and treatment.     

 

• The biopsy segment accounted for the largest market share in 2024 and is projected to grow at a notable CAGR during the forecast period.        

Based on the diagnosis, the desmoid tumors market is segmented into biopsy, electron microscopic examination, immunohistochemical analysis, and other diagnoses. Among these, the biopsy segment accounted for the largest market share in 2024 and is projected to grow at a notable CAGR during the forecast period. Its use in oncology and its proven reliability, biopsy is the primary way to diagnose desmoid tumors. Also, it provides a definitive diagnosis, which is essential for developing a treatment plan.

 

• The surgery segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.      

Based on the treatment, the desmoid tumors market is divided into surgery, radiation therapy, hormone therapy, and other treatments. Among these, the surgery segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Surgery is critical in treating desmoid tumors because it can provide permanent relief from the tumor and allow for long-lasting remission. Desmoid tumors are challenging to treat and have a high rate of recurrence. Cases may be treated with adjunct therapies such as radiation therapy or hormonal therapy to improve treatment outcomes.

Regional Segment Analysis of the Desmoid Tumors Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

Asia Pacific is anticipated to hold the largest share of the desmoid tumors market over the predicted timeframe.     

Asia Pacific is anticipated to hold the largest share of the desmoid tumors market over the predicted timeframe. In the Asia-Pacific area, there are extensive opportunities for expansion as a result of the quick development of health care systems and services throughout the Asia-Pacific region of the world. The booming economies of China and India are examples of emerging markets and are largely responsible for this rapid expansion. The rise in rates of people diagnosed with desmoid tumors, in conjunction with an increase in knowledge of these tumors among professionals and patients, is creating a large demand for effective therapies for this disease. Furthermore, improved access to and affordability of health care in the Asia-Pacific region will be beneficial for the future growth of the market.

 

North America is expected to grow at a rapid CAGR in the desmoid tumors market during the forecast period. The North American share of the global market is substantial due to a well-developed health care system, strong diagnostic and treatment technology, and high awareness of desmoid tumors in the region. Research and development is emphasized among North America, and collaboration between key stakeholders supports that focus. Furthermore, because of advances in treatment and increased spending by hospitals on their programs, the North American market will continue to expand at a steady rate.

 

The FDA approved Ogsiveo (nirogacestat), the first drug for desmoid tumors—rare, non-cancerous but aggressive growths. It offers systemic treatment beyond surgery, reducing recurrence risks and improving patient quality of life.

 

Competitive Analysis:   

The report offers the appropriate analysis of the key organizations/companies involved within the desmoid tumors market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.  

 

List of Key Companies

• Alembic Pharmaceuticals Limited
• Amneal Pharmaceuticals LLC
• Apotex Inc.
• Assertio Holdings, Inc.
• Bayer AG
• Hikma Pharmaceuticals PLC
• Horizon Therapeutics Plc
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd
• Zydus Lifesciences
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

 

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the desmoid tumors market based on the below-mentioned segments: 

  

Global Desmoid Tumors Market, By Diagnosis

• Biopsy
• Electron Microscopic Examination
• Immunohistochemical Analysis
• Other Diagnosis

 

Global Desmoid Tumors Market, By Treatment

• Surgery
• Radiation Therapy
• Hormone Therapy
• Other Treatments

 

Global Desmoid Tumors Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

 

1. What is the projected size and growth rate of the global desmoid tumors market?

The market was valued at USD 2.65 billion in 2024 and is expected to reach USD 4.76 billion by 2035, growing at a CAGR of 5.47% from 2025 to 2035, driven by improved diagnostics and treatment innovations.

 

2. What are desmoid tumors, and why are they challenging to manage?

Desmoid tumors are rare, noncancerous (benign) growths in connective tissues like muscles and tendons. They aggressively invade nearby tissues, often recur after treatment, and can cause pain, swelling, or complications like nerve compression, making diagnosis and management complex.

 

3. Which diagnosis method dominates the market, and why?

Biopsy holds the largest market share in 2024 and is projected to grow at a notable CAGR. It provides definitive confirmation by distinguishing desmoid tumors from other conditions, essential for accurate treatment planning.

 

4. What is the leading treatment segment in the market?

Surgery accounted for the highest revenue in 2024 and is expected to grow at a significant CAGR. It offers potential for long-term remission, often combined with radiation or hormone therapy to address high recurrence rates.

 

5. Which regions are leading or growing fastest in the desmoid tumors market?

Asia-Pacific is anticipated to hold the largest share due to rapid healthcare expansion in countries like China and India, rising diagnoses, and improved access. North America is poised for the fastest growth, fueled by advanced infrastructure, R&D, and high awareness.

 

6. What recent developments are shaping the market?

The FDA approved Ogsiveo (nirogacestat) as the first systemic drug for desmoid tumors, reducing reliance on surgery. Additionally, biotech funding like Parabilis's $305 million Series F round is accelerating targeted therapies and personalised medicine.